Assyro AI

Purple Book product · Interchangeable

Yesintek

ustekinumab-kfce

351(k) InterchangeableBLA 761406RxLicensed Biocon Biologics Inc.

Nov 29, 2024

Approved

Interchangeable

License type

Rx

Marketing

12

Listed patents

Yesintek (ustekinumab-kfce) is a Interchangeable referencing ustekinumab, licensed under a 351(k) BLA in 2024 and marketed by Biocon Biologics Inc.. As an interchangeable biosimilar it may be substituted for the reference product at the pharmacy without prescriber involvement, subject to state law. The Purple Book lists 12 published patents for this product.

Sourced from the FDA Purple Book · verified Jul 02, 2026

Key dates

  1. Approval

    Approval date of this BLA submission.

    Nov 29, 2024

    1 yr 8 mo ago

  2. Today

Pharmaceutical detail

Strength

130MG/26ML (5MG/ML)

Dosage form

Injection

Route

Intravenous

Presentation

Single-Dose Vial

Center

CDER

License number

2324

Product number

004

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

Biosimilar of ustekinumab (Stelara)

Patent list (12)

Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
PatentExpiresInSource
6,902,734Sep 25, 20232 yr 10 mo agoFDA
6,902,734Sep 25, 20232 yr 10 mo agoFDA
8,852,889Jul 06, 2032in 6 yr 1 moFDA
8,852,889Jul 06, 2032in 6 yr 1 moFDA
9,475,858Jul 06, 2032in 6 yr 1 moFDA
9,475,858Jul 06, 2032in 6 yr 1 moFDA
9,217,168Mar 14, 2033in 6 yr 9 moFDA
9,217,168Mar 14, 2033in 6 yr 9 moFDA
9,663,810Mar 14, 2033in 6 yr 9 moFDA
9,663,810Mar 14, 2033in 6 yr 9 moFDA
10,961,307Sep 24, 2039in 13 yr 5 moFDA
10,961,307Sep 24, 2039in 13 yr 5 moFDA

Source provenance

Source kind · Advanced Search
Checked Jul 02, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

Change history

  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Frequently asked questions

When do Yesintek's patents expire?

The FDA Purple Book lists 12 published patents for Yesintek, with the last listed patent expiring Sep 24, 2039. Every patent below links to its FDA source record so you can verify the expiration date.

Is Yesintek a biosimilar?

Yes. Yesintek is a Interchangeable referencing ustekinumab, licensed under a 351(k) BLA.

Is Yesintek interchangeable?

Yes. Yesintek carries an FDA interchangeability designation, so it may be substituted for the reference product at the pharmacy without prescriber involvement, subject to state law.

What is Yesintek's BLA number?

Yesintek is licensed under BLA 761406, held by Biocon Biologics Inc..

When was Yesintek approved by the FDA?

Yesintek was approved by the FDA on Nov 29, 2024.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.